# US 2008/0306269 A1 · Intermediates useful for making tetrabenazine compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306269 A1
- Document ID: US20080306269A1
- Status: Published application
- Kind: A1
- Application number: 11/760,372
- Filed: 2007-06-08
- Published: 2008-12-11
- Earliest claimed: 2007-06-08
- Assignees: General Electric Company
- Inventors: Michael James Rishel; Kande Kankananamalage Dayarathna Amarasinghe; Sean Richard Dinn; Bruce Fletcher Johnson
- Web page: https://patentgrep.com/patent/US20080306269A1

## CPC

- C07D 455/06: containing benzo [a] quinolizine ring systems
- C07D 217/16: substituted by oxygen atoms
- C07D 217/18: Aralkyl radicals
- Y02P 20/55: Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

A method of preparing a tetrabenazine compound (TBZ compound) having structure I comprising the steps of reacting a nucleophilic alkenyl species with aldehyde compound II and oxidizing the resultant allylic alcohol to provide enone III. The protecting group P1 on the tetrahydroisoquinoline nitrogen is removed and the resultant deprotected intermediate is induced to undergo an amino cyclization reaction to provide a product TBZ compound having structure I. The method may be used to prepare either enantiomeric form of tetrabenazine; (+)-tetrabenazine or (−)-tetrabenazine. Alternatively the method may be adapted to provide a mixture enriched in one tetrabenazine enantiomer, a racemic mixture, or a diastereomeric mixture of tetrabenazine compounds. In addition, the present invention provides novel synthetic intermediate compositions which may be used to prepare either or both enantiomers of tetrabenazine, derivatives of tetrabenazine, and analogs of tetrabenazine.

## Claims

### Claim 1

A tetrahydroisoquinoline compound having structure III
wherein R1-R4 are independently hydrogen or an isotope thereof, a halogen atom, a C1-C20 aliphatic radical, a C2-C20 cycloaliphatic radical, or a C2-C20 aromatic radical, wherein at least one of R1-R4 is not hydrogen; R5-R11 are independently hydrogen or an isotope thereof, a C1-C20 aliphatic radical, a C2-C20 cycloaliphatic radical, or a C2-C20 aromatic radical; and P1 is a protecting group.

### Claim 2 (depends on 1)

The tetrahydroisoquinoline compound according to claim 1, wherein said protecting group P1 comprises a carbonyl group.

### Claim 3 (depends on 1)

The tetrahydroisoquinoline compound according to claim 1, wherein the protecting group P1 is selected from the group consisting of Boc, Fmoc, Cbz, Alloc, benzyl, and t-butyl.

### Claim 4 (depends on 1)

The tetrahydroisoquinoline compound according to claim 1, wherein the protecting group P1 is a Boc group.

### Claim 5 (depends on 1)

The tetrahydroisoquinoline compound according to claim 1, which is enantiomerically enriched.

### Claim 6 (depends on 5)

The tetrahydroisoquinoline compound according to claim 5, at least 95 mole % of which is comprised of an enantiomer having the R configuration at ring position-12.

### Claim 7 (depends on 5)

The tetrahydroisoquinoline compound according to claim 5, at least 95 mole % of which is comprised of an enantiomer having the S configuration at ring position-12.

### Claim 8

A tetrahydroisoquinoline compound having structure XI
wherein R1-R4 are independently hydrogen or an isotope thereof, a halogen atom, a C1-C20 aliphatic radical, a C2-C20 cycloaliphatic radical, or a C2-C20 aromatic radical, wherein at least one of R1-R4 is not hydrogen; and R5-R11 are independently hydrogen or an isotope thereof, a C1-C20 aliphatic radical, a C2-C20 cycloaliphatic radical, or a C2-C20 aromatic radical.

### Claim 9

A tetrahydroisoquinoline compound having structure XII
wherein R1-R4 are independently hydrogen or an isotope thereof, a halogen atom, a C1-C20 aliphatic radical, a C2-C20 cycloaliphatic radical, or a C2-C20 aromatic radical, wherein at least one of R1-R4 is not hydrogen; R5-R11 are independently hydrogen or an isotope thereof, a C1-C20 aliphatic radical, a C2-C20 cycloaliphatic radical, or a C2-C20 aromatic radical; P1 is a protecting group; and Q1 is hydrogen or an isotope thereof.

### Claim 10 (depends on 9)

The tetrahydroisoquinoline compound according to claim 9, which is enantiomerically enriched.

### Claim 11 (depends on 10)

The tetrahydroisoquinoline compound according to claim 10, at least 95 mole % of which is comprised of an enantiomer having the R configuration at ring position-12.

### Claim 12 (depends on 10)

The tetrahydroisoquinoline compound according to claim 10, at least 95 mole % of which is comprised of an enantiomer having the S configuration at ring position-12.

### Claim 13

A tetrahydroisoquinoline compound having structure XIII
wherein R1-R4 are independently hydrogen or an isotope thereof, a halogen atom, a C1-C20 aliphatic radical, a C2-C20 cycloaliphatic radical, or a C2-C20 aromatic radical, wherein at least one of R1-R4 is not hydrogen; R5-R11 are independently hydrogen or an isotope thereof, a C1-C20 aliphatic radical, a C2-C20 cycloaliphatic radical, or a C2-C20 aromatic radical; and Q1 is hydrogen or an isotope thereof.

### Claim 14

A tetrahydroisoquinoline compound having structure VII
wherein R2-R3 are independently hydrogen or an isotope thereof, a halogen atom, a C1-C20 aliphatic radical, a C2-C20 cycloaliphatic radical, or a C2-C20 aromatic radical, wherein at least one of R2-R3 is not hydrogen; R11 is hydrogen or an isotope thereof, a C1-C20 aliphatic radical, a C2-C20 cycloaliphatic radical, or a C2-C20 aromatic radical; and P1 is a protecting group.

### Claim 15 (depends on 14)

The tetrahydroisoquinoline compound according to claim 14, which is enantiomerically enriched.

### Claim 16 (depends on 15)

The composition according to claim 15, at least 95 mole % of which is comprised of an enantiomer having the R configuration at ring position-12.

### Claim 17 (depends on 15)

The composition according to claim 15, at least 95 mole % of which is comprised of an enantiomer having the S configuration at ring position-12.

### Claim 18

A tetrahydroisoquinoline compound having structure XIV
wherein R2-R3 are independently hydrogen or an isotope thereof, a halogen atom, a C1-C20 aliphatic radical, a C2-C20 cycloaliphatic radical, or a C2-C20 aromatic radical, wherein at least one of R2-R3 is not hydrogen; and R11 is hydrogen or an isotope thereof, a C1-C20 aliphatic radical, a C2-C20 cycloaliphatic radical, or a C2-C20 aromatic radical.

### Claim 19 (depends on 18)

The tetrahydroisoquinoline compound according to claim 18, which is enantiomerically enriched.

### Claim 20 (depends on 19)

The tetrahydroisoquinoline compound according to claim 19, at least 95 mole % of which is comprised of an enantiomer having the R configuration at ring position-12.

### Claim 21 (depends on 19)

The tetrahydroisoquinoline compound according to claim 19, at least 95 mole % of which is comprised of an enantiomer having the S configuration at ring position-12.

### Claim 22

A tetrahydroisoquinoline compound having structure XV

### Claim 23

A tetrahydroisoquinoline compound having structure XVI
